Pacritinib for treating VEXAS syndrome
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called pacritinib for people with VEXAS syndrome. It aims to see if pacritinib can help control inflammation and reduce the need for steroids. You may qualify if you have a specific UBA1 gene mutation and are currently on a stable steroid dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed change (mutation) in the UBA1 gene at a specific spot called M41 or nearby.
- You must have had inflammation in at least one organ system (like skin, joints, eyes, or lungs) due to VEXAS in the past 6 months.
- You need to be taking a stable dose of prednisone or prednisolone (15 to 45 mg every day).
- You should be able to do most daily activities on your own (Karnofsky score of 50% or more).
- Your liver, kidney, and blood cell counts must meet certain safe levels (checked by blood tests).
- You cannot have had a stem cell or organ transplant, more than one ICU stay for VEXAS in 6 months, or certain other conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called pacritinib for people with VEXAS syndrome, a rare autoinflammatory condition. The goal is to see if pacritinib can help control symptoms like rashes, joint pain, and low blood counts.
This trial tests whether a new drug called momelotinib can help treat VEXAS syndrome, a rare genetic inflammatory condition. The study will see if it can reduce inflammation and allow patients to use less steroid medication.
This study tests an investigational drug called arumakimig (MAS825) in people with VEXAS, a rare genetic condition that causes inflammation. The trial checks if the drug helps control symptoms and improve quality of life.
This trial looks for people age 50+ with unexplained inflammation or blood problems like anemia or low platelets. It aims to better identify a rare condition called VEXAS syndrome, which causes these symptoms.
This study looks at how VEXAS syndrome affects your daily life and finances. It aims to understand the challenges you face so doctors can better support you.
This trial tests an experimental drug called VTX2735 for people with recurring pericarditis (inflammation around the heart). It aims to see if the drug can help reduce pain and inflammation during a flare-up.
Hear when a new VEXAS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.